GO:0075713 establishment of integrated proviral latency: Viral Integration Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0075713 (establishment of integrated proviral latency) describes the biological process by which a virus integrates its genome into the host genome and persists as a stable provirus or prophage [1, 8].
• The process is central to the life cycles of retroviruses, foamy viruses, herpesviruses, and adeno-associated virus, and it underlies persistent infections and oncogenesis [2, 3, 6].
• HIV-1 capsid uncoating location directly dictates where integration occurs in the host genome, linking capsid biology to integration site selection [4, 7].
• Integration is not random: capsid-dependent host factors and chromatin context influence proviral latency establishment.
• Ancient viral integrations have left genomic fossils in eukaryotic genomes, making this process relevant to evolution and genome stability.
• Studying GO:0075713 requires virological, genomic, and CRISPR-based approaches to dissect host factors and integration sites [1, 4, 7].
Description
Establishment of integrated proviral latency (GO:0075713) is the biological process through which a virus inserts its genetic material into the host genome and remains there as a stable provirus or prophage [1, 8]. This process is a defining feature of retroviruses such as HIV-1, but it is also employed by foamy viruses, herpesviruses, and adeno-associated virus vectors [2, 3, 6]. The integrated provirus can persist for the lifetime of the host cell and may be transmitted to daughter cells, creating a reservoir that is difficult to eliminate [1, 7]. Understanding how integration is established is therefore fundamental to virology, gene therapy, and the study of virus-driven cancers [2, 6]. Mechanistically, integration begins with viral entry and reverse transcription, followed by nuclear import of the pre-integration complex and strand transfer into host DNA [1, 4]. Recent work shows that the subcellular location of HIV-1 capsid uncoating determines the sites of integration, revealing a tight coupling between capsid fate and genomic targeting. Capsid-dependent host factors further modulate this process, influencing both efficiency and site selection. In the case of foamy viruses, integration occurs through a distinct mechanism that still results in stable proviral latency. For researchers, GO:0075713 provides a framework to study how viruses achieve persistent infection, how integration site selection contributes to oncogenesis, and how gene therapy vectors can be designed for safe and durable expression [2, 6, 8]. Because integrated proviruses are permanent, they represent both a therapeutic challenge and a powerful tool for stable gene delivery [2, 7].
establishment of integrated proviral latency At A Glance
| GO ID | GO:0075713 |
|---|---|
| GO term | establishment of integrated proviral latency |
| Ontology | biological_process |
| Synonym | prophage integration; provirus integration |
| Definition | A process by which the virus integrates into the host genome and establishes as a stable provirus or prophage. |
| Major function | Stable insertion of viral genetic material into the host genome, enabling persistent infection and latency. |
| Related processes | Viral integration, reverse transcription, nuclear import, latency establishment. |
| Representative viruses | Retroviruses (e.g., HIV-1), foamy viruses, herpesviruses, adeno-associated virus. |
| Research relevance | Antiviral targets, gene therapy vector design, oncogenesis, viral latency reservoirs. |
What Is GO:0075713?
According to the Gene Ontology, GO:0075713 (establishment of integrated proviral latency) is the process by which a virus integrates into the host genome and establishes itself as a stable provirus or prophage [1, 8]. This definition encompasses the molecular events that lead to covalent insertion of viral DNA into host DNA and the subsequent maintenance of the integrated viral genome in a latent state [1, 3, 6].
Why Is establishment of integrated proviral latency Important in Cell Biology?
GO:0075713 is critically important because integrated proviral latency is a hallmark of persistent viral infections and a major barrier to curing diseases such as HIV-1 [1, 7]. The process also underlies the oncogenic potential of viruses that insert near proto-oncogenes, and it is exploited in gene therapy vectors for stable transgene expression [2, 6]. Understanding the mechanisms of integration can inform the development of drugs that block integration or reactivate latent reservoirs [4, 7].
• Enables lifelong persistence of retroviruses such as HIV-1, creating a viral reservoir that is refractory to current therapies [1, 7].
• Drives oncogenesis when integration disrupts tumor suppressor genes or activates proto-oncogenes, as seen with herpesviruses and retroviruses.
• Underpins gene therapy approaches using adeno-associated virus and lentiviral vectors for stable gene delivery.
• Provides a model for studying virus-host genome interactions and chromatin targeting [4, 7].
• Explains the presence of endogenous viral elements in eukaryotic genomes, offering insights into evolution.
• Informs the design of integrase inhibitors and latency-reversing agents [1, 4].
• Requires capsid-dependent host factors, making these factors potential antiviral targets.
• Foamy virus integration serves as a unique model for non-pathogenic proviral latency.
• Herpesvirus integration can lead to chromosomal instability and is associated with certain cancers.
• Understanding integration site selection is essential for predicting insertional mutagenesis risks in gene therapy [2, 6].
What Happens During establishment of integrated proviral latency?
Viral Entry and Capsid Uncoating
In simple terms: The virus enters the cell and its protective shell, the capsid, opens up at a specific location.
The establishment of integrated proviral latency begins with viral entry and the timely uncoating of the viral capsid. For HIV-1, the location of capsid uncoating within the cell dictates the subsequent sites of integration, linking early trafficking events to genomic targeting. The retrovirus capsid core plays a central role in protecting the viral genome and coordinating reverse transcription with uncoating. Capsid-dependent host factors, such as CPSF6 and NUP153, interact with the capsid to influence nuclear import and integration site selection.
Reverse Transcription and Pre-Integration Complex Formation
In simple terms: The viral RNA is converted into DNA, which then forms a complex with viral and host proteins ready to enter the nucleus.
Following uncoating, the viral RNA genome is reverse transcribed into double-stranded DNA within the capsid core or at the nuclear pore. The resulting pre-integration complex (PIC) contains viral integrase, reverse transcriptase, and host factors. The PIC is then transported into the nucleus, a step that is dependent on capsid-host interactions. For foamy viruses, reverse transcription and integration occur through a distinct pathway that still leads to stable proviral latency.
Nuclear Import and Chromatin Targeting
In simple terms: The viral DNA complex enters the nucleus and finds a suitable spot in the host genome to insert itself.
Nuclear import of the PIC is a regulated step that determines the accessibility of integration sites. HIV-1 capsid uncoating location influences whether integration occurs in gene-rich, transcriptionally active regions or in heterochromatin. Host factors such as LEDGF/p75 tether integrase to chromatin, favoring integration into active genes. In herpesviruses, integration can occur at specific chromosomal sites, potentially leading to genomic instability.
Strand Transfer and Provirus Formation
In simple terms: The viral DNA is stitched into the host DNA, becoming a permanent part of the cell's genetic material.
The final step of integration involves strand transfer, catalyzed by viral integrase, which covalently joins the viral DNA ends to host DNA. This creates a provirus that is flanked by duplicated host sequences. For retroviruses, the integrated provirus can remain latent or become transcriptionally active depending on the chromatin environment and viral regulatory proteins. Adeno-associated virus vectors also establish latent proviral forms, often as episomes or integrated concatemers.
Latency Establishment and Maintenance
In simple terms: After integration, the virus can stay silent for a long time, hiding from the immune system.
Once integrated, the provirus can enter a latent state characterized by minimal viral gene expression. This latency is maintained by epigenetic modifications, including histone deacetylation and DNA methylation, as well as by the absence of activating transcription factors. In HIV-1, latency is established preferentially in memory CD4+ T cells, creating a long-lived reservoir. Herpesviruses can also establish latent infections with integrated or episomal genomes, contributing to persistent infections.
Key Genes Involved in GO:0075713 establishment of integrated proviral latency
The following genes and proteins are key players in the establishment of integrated proviral latency, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IN (HIV-1 integrase) | Catalyzes strand transfer of viral DNA into host genome | Primary target for integrase inhibitors; essential for provirus formation |
| CA (HIV-1 capsid) | Protects viral genome and coordinates uncoating | Determines integration site selection; target for capsid inhibitors [4, 7] |
| LEDGF/p75 (PSIP1) | Tethers integrase to chromatin | Directs integration into active genes; knockout reduces integration efficiency |
| CPSF6 | Binds capsid and influences nuclear import | Modulates integration site selection; knockdown alters targeting |
| NUP153 | Nuclear pore protein interacting with capsid | Required for nuclear import of PIC; affects integration |
| TNPO3 | Transportin 3, mediates capsid nuclear import | Host factor for HIV-1 integration; knockout impairs infection |
| MX2 | Interferon-induced restriction factor | Inhibits nuclear import of HIV-1; affects integration |
| TRIM5α | Restriction factor recognizing capsid | Species-specific block to infection; influences uncoating |
| Cyclophilin A (PPIA) | Binds capsid and modulates uncoating | Regulates capsid stability; affects integration [1, 7] |
| Integrase (foamy virus) | Catalyzes integration in foamy viruses | Unique integration mechanism; model for non-pathogenic latency |
| Herpesvirus integrase (e.g., HHV-6) | Mediates chromosomal integration | Associated with chromosomal instability and disease |
| AAV Rep proteins | Mediate site-specific integration | Used in gene therapy vectors; integration at AAVS1 |
| BAF (BANF1) | Barrier-to-autointegration factor | Binds DNA and compacts retroviral DNA; affects integration |
| HMGA1 | Chromatin architectural protein | Facilitates integration into chromatin |
| INI1/hSNF5 (SMARCB1) | Component of SWI/SNF chromatin remodeling complex | Interacts with integrase; influences integration |
| LEDGF (PSIP1) splice variants | Chromatin reader | Modulate integration site preference |
| SUN1/2 | Nuclear envelope proteins | Involved in nuclear import of HIV-1 |
| Transportin-SR2 (TNPO3) | Nuclear import receptor | Required for HIV-1 integration |
How Is establishment of integrated proviral latency Regulated?
The establishment of integrated proviral latency is regulated at multiple levels. Viral capsid uncoating location is a key determinant of integration site selection, and this process is influenced by host factors such as CPSF6 and NUP153 [4, 7]. Chromatin accessibility and epigenetic modifications also regulate whether an integrated provirus remains latent or becomes transcriptionally active. In addition, interferon-induced restriction factors like MX2 and TRIM5α can block steps prior to integration, thereby modulating the efficiency of latency establishment [1, 7]. For foamy viruses, integration is regulated by unique viral and host determinants that differ from orthoretroviruses.
establishment of integrated proviral latency and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IN (HIV-1 integrase) | HIV/AIDS latency | Knockout of IN in proviral clones; point mutations to study strand transfer |
| LEDGF/p75 (PSIP1) | HIV-1 integration site selection | Knockout cell lines; overexpression of mutants |
| CPSF6 | HIV-1 nuclear import and integration | Knockout and knock-in of capsid-binding domain mutants |
| HHV-6 integrase | Chromosomal instability and cancer | Knock-in of viral integrase into cell lines; integration site mapping |
| AAV Rep | Gene therapy insertional mutagenesis | Knockout of Rep in AAV vectors; integration site analysis |
HIV-1 Latency and AIDS
HIV-1 establishes integrated proviral latency in CD4+ T cells and macrophages, creating a viral reservoir that persists despite antiretroviral therapy [1, 7]. The site of integration and the epigenetic state of the provirus determine whether the virus remains latent or reactivates. Understanding GO:0075713 is essential for developing strategies to eliminate the latent reservoir, such as shock-and-kill approaches [4, 7].
Virus-Induced Cancers
Integration of viral genomes can cause cancer by insertional mutagenesis. Herpesviruses, such as human herpesvirus 6, can integrate into host chromosomes and are associated with chromosomal instability and malignancies. Retroviruses can activate proto-oncogenes or disrupt tumor suppressors upon integration, contributing to leukemias and lymphomas.
Gene Therapy and Insertional Mutagenesis
Adeno-associated virus and lentiviral vectors establish integrated proviral latency to achieve stable transgene expression in gene therapy. However, integration carries a risk of insertional mutagenesis, as seen in early retroviral gene therapy trials. Understanding integration site selection is critical for designing safer vectors [2, 6].
Endogenous Viral Elements and Evolution
Ancient viral integrations have become fixed in eukaryotic genomes as endogenous viral elements, providing a record of past infections. These elements can influence host gene regulation and genome evolution, and some have been co-opted for host functions. Studying GO:0075713 helps explain how these fossils arose and their impact on modern genomes.
From establishment of integrated proviral latency-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a host factor promote HIV-1 integration? | Knockout cell lines (e.g., CRISPR KO of PSIP1, CPSF6) followed by infection and integration site sequencing |
| How does a point mutation in integrase affect strand transfer? | Point-mutation knock-in of IN in proviral clones; in vitro strand transfer assays |
| Where does the provirus integrate in the genome? | Knock-in of tagged integrase; integration site sequencing (e.g., linker-mediated PCR) |
| Can overexpression of a restriction factor block integration? | Overexpression cell lines (e.g., MX2, TRIM5α) followed by challenge with HIV-1 |
| What is the role of capsid uncoating location? | Tagged knock-in of capsid with fluorescent markers; live-cell imaging |
| Does a viral protein establish latency? | Knockout of viral latency-associated transcripts; latency reactivation assays |
How to Study the establishment of integrated proviral latency Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Integration site sequencing | Genomic locations of proviral insertions | Mapping HIV-1 integration sites in patient samples |
| CRISPR knockout screen | Host genes affecting integration | Identifying novel restriction factors |
| Live-cell imaging | Capsid uncoating and nuclear import dynamics | Studying spatiotemporal regulation of integration |
| Latency reactivation assay | Ability to reverse proviral latency | Testing latency-reversing agents |
| qPCR for integrated DNA | Quantity of integrated provirus | Measuring integration efficiency |
| In vitro strand transfer assay | Integrase catalytic activity | Screening integrase inhibitors |
| Chromatin immunoprecipitation (ChIP) | Protein-DNA interactions at integration sites | Studying chromatin factors at provirus |
| RNA-seq | Viral and host gene expression | Assessing latency and reactivation |
Integration Site Sequencing
Integration site sequencing (e.g., linker-mediated PCR, next-generation sequencing) identifies where proviruses insert in the host genome. This method is essential for studying site selection and clonal expansion of latently infected cells [4, 7].
CRISPR Screens for Host Factors
Genome-wide CRISPR knockout or activation screens can identify host genes that promote or restrict establishment of integrated proviral latency. Hits are validated by individual KO and infection assays.
Live-Cell Imaging of Capsid Uncoating
Fluorescently tagged capsid and nuclear markers allow real-time visualization of uncoating and nuclear import. This reveals the spatiotemporal coupling between uncoating and integration.
Latency Reactivation Assays
Latency reactivation assays measure the ability of stimuli (e.g., HDAC inhibitors, PKC agonists) to induce viral gene expression from integrated proviruses. These assays are used to study the maintenance of latency and to test shock-and-kill strategies.
How CRISPR Can Be Used to Study GO:0075713 establishment of integrated proviral latency
Knockout
CRISPR knockout of host genes such as PSIP1, CPSF6, or TNPO3 can reveal their requirement for establishment of integrated proviral latency. For example, knocking out PSIP1 reduces HIV-1 integration efficiency and alters integration site distribution.
Point Mutation
Point mutations in viral integrase or capsid can be introduced using CRISPR knock-in to study specific residues involved in strand transfer or uncoating. This approach helps dissect the molecular mechanism of integration [1, 4].
Knock-in
Knock-in of tagged versions of viral proteins (e.g., fluorescent capsid) or host factors allows visualization and purification of complexes involved in integration. Tagged knock-in models are valuable for live-cell imaging and proteomics.
Overexpression
Overexpression of restriction factors like MX2 or TRIM5α can block integration and latency establishment. CRISPR activation (CRISPRa) can be used to overexpress endogenous genes to study their antiviral effects.
How EDITGENE Supports establishment of integrated proviral latency Research
Researchers studying establishment of integrated proviral latency-related genes often need to determine whether a candidate gene is causally involved in viral integration, latency maintenance, or restriction. EDITGENE provides a comprehensive suite of CRISPR-based services to enable these investigations.
Contact EDITGENE today to design your custom CRISPR model for establishment of integrated proviral latency research.
Frequently Asked Questions About establishment of integrated proviral latency
What is GO:0075713 establishment of integrated proviral latency?
GO:0075713 is a Gene Ontology biological process term describing how a virus integrates its genome into the host genome and establishes a stable provirus or prophage [1, 8].
What genes are involved in establishment of integrated proviral latency?
Key genes include HIV-1 integrase (IN), capsid (CA), and host factors such as LEDGF/p75 (PSIP1), CPSF6, NUP153, and TNPO3 [1, 4, 7].
How does HIV-1 establish latent provirus?
HIV-1 integrates its reverse-transcribed DNA into host chromatin, preferentially in active genes, and can remain latent depending on epigenetic and transcriptional conditions [1, 7].
What is the role of capsid uncoating in integration?
The location of capsid uncoating dictates the sites of integration, linking early trafficking to genomic targeting.
Which viruses use integrated proviral latency?
Retroviruses (e.g., HIV-1), foamy viruses, herpesviruses, and adeno-associated virus vectors can establish integrated proviral latency [2, 3, 6].
How can CRISPR be used to study proviral latency?
CRISPR knockout, knock-in, and activation screens can identify and validate host factors that regulate integration and latency.
What diseases are associated with integrated proviral latency?
HIV/AIDS, virus-induced cancers, and insertional mutagenesis in gene therapy are major disease contexts [1, 2, 6].
What methods measure integration sites?
Integration site sequencing, linker-mediated PCR, and next-generation sequencing are commonly used to map proviral insertions [4, 7].
Can latency be reversed?
Latency-reversing agents such as HDAC inhibitors can reactivate proviruses, but eliminating the reservoir remains challenging.
Why is foamy virus integration important?
Foamy viruses use a distinct integration mechanism and are non-pathogenic, serving as a model for safe gene therapy vectors.
Conclusion
GO:0075713 (establishment of integrated proviral latency) is a fundamental biological process that enables viruses to persist in host cells and cause chronic diseases. It is driven by coordinated actions of viral proteins and host factors, with capsid uncoating location and chromatin context playing decisive roles [1, 4, 7]. Understanding this process is essential for developing antiviral therapies, improving gene therapy vectors, and deciphering the evolutionary impact of ancient viral integrations [2, 6, 8]. EDITGENE provides advanced CRISPR tools and services to dissect the genes and mechanisms underlying proviral latency, empowering researchers to translate discoveries into clinical applications.
References
- 1. Zhang W et al.. 2018. The Retrovirus Capsid Core.. Subcell Biochem 88:169-187 PMID: 29900497
- 2. Carter BJ. 1992. Adeno-associated virus vectors.. Curr Opin Biotechnol 3(5):533-9 PMID: 1369403
- 3. Juretzek T et al.. 2004. Foamy virus integration.. J Virol 78(5):2472-7 PMID: 14963145
- 4. Burdick RC et al.. 2026. HIV-1 uncoating location dictates sites of integration.. Nat Commun 17(1) PMID: 41957012
- 6. Morissette G et al.. 2010. Herpesviruses and chromosomal integration.. J Virol 84(23):12100-9 PMID: 20844040
- 7. Yamashita M et al.. 2017. Capsid-Dependent Host Factors in HIV-1 Infection.. Trends Microbiol 25(9):741-755 PMID: 28528781
- 8. Tomonaga K et al.. 2019. "Integration of viral sequences into eukaryotic host genomes: legacy of ancient infections".. Virus Res 262:1 PMID: 30732705
